WO2016117508A1 - 虚血性疾患治療薬 - Google Patents
虚血性疾患治療薬 Download PDFInfo
- Publication number
- WO2016117508A1 WO2016117508A1 PCT/JP2016/051293 JP2016051293W WO2016117508A1 WO 2016117508 A1 WO2016117508 A1 WO 2016117508A1 JP 2016051293 W JP2016051293 W JP 2016051293W WO 2016117508 A1 WO2016117508 A1 WO 2016117508A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- plasmid
- seq
- transformation
- growth factor
- bifidobacterium
- Prior art date
Links
- 208000023589 ischemic disease Diseases 0.000 title claims abstract description 54
- 239000003814 drug Substances 0.000 title description 4
- 229940124597 therapeutic agent Drugs 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 164
- 239000013612 plasmid Substances 0.000 claims abstract description 134
- 230000009466 transformation Effects 0.000 claims abstract description 72
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 66
- 230000003248 secreting effect Effects 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 24
- 241000186000 Bifidobacterium Species 0.000 claims description 57
- 241000894006 Bacteria Species 0.000 claims description 43
- 150000001413 amino acids Chemical class 0.000 claims description 43
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 32
- 241001608472 Bifidobacterium longum Species 0.000 claims description 28
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 28
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 27
- 229940024606 amino acid Drugs 0.000 claims description 26
- 241001148471 unidentified anaerobic bacterium Species 0.000 claims description 26
- 238000003745 diagnosis Methods 0.000 claims description 20
- 101800001707 Spacer peptide Proteins 0.000 claims description 17
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 9
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 9
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 9
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 8
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 7
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 6
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 6
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 6
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 6
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 6
- 102000013275 Somatomedins Human genes 0.000 claims description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 6
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 6
- 229940053128 nerve growth factor Drugs 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 6
- 238000007910 systemic administration Methods 0.000 claims description 6
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 5
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 5
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 5
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 5
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 5
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims description 5
- 239000003102 growth factor Substances 0.000 claims description 5
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 4
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- 102000009840 Angiopoietins Human genes 0.000 claims description 3
- 108010009906 Angiopoietins Proteins 0.000 claims description 3
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 3
- 108010041308 Endothelial Growth Factors Proteins 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 229940047120 colony stimulating factors Drugs 0.000 claims description 3
- 108060002566 ephrin Proteins 0.000 claims description 3
- 102000012803 ephrin Human genes 0.000 claims description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 3
- 150000003180 prostaglandins Chemical class 0.000 claims description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 3
- 230000006444 vascular growth Effects 0.000 claims description 3
- 230000024883 vasodilation Effects 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 claims description 2
- 102100029268 Neurotrophin-3 Human genes 0.000 claims description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 2
- 229960000511 lactulose Drugs 0.000 claims description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 2
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 claims description 2
- 229940032018 neurotrophin 3 Drugs 0.000 claims description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102100031372 Thymidine phosphorylase Human genes 0.000 claims 1
- 108700023160 Thymidine phosphorylases Proteins 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 230000001023 pro-angiogenic effect Effects 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 13
- 230000001131 transforming effect Effects 0.000 abstract description 7
- 238000001476 gene delivery Methods 0.000 abstract 4
- 239000012634 fragment Substances 0.000 description 53
- 230000032258 transport Effects 0.000 description 50
- 230000028327 secretion Effects 0.000 description 43
- 238000006243 chemical reaction Methods 0.000 description 40
- 239000000243 solution Substances 0.000 description 40
- 108020004414 DNA Proteins 0.000 description 38
- 101100281008 Homo sapiens FGF2 gene Proteins 0.000 description 33
- 239000002609 medium Substances 0.000 description 31
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 25
- 102100022465 Methanethiol oxidase Human genes 0.000 description 25
- 101710134383 Methanethiol oxidase Proteins 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 25
- 239000013598 vector Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 19
- 241000588724 Escherichia coli Species 0.000 description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 238000001802 infusion Methods 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 230000017531 blood circulation Effects 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 13
- 230000033115 angiogenesis Effects 0.000 description 12
- 229960000268 spectinomycin Drugs 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000012408 PCR amplification Methods 0.000 description 10
- 239000012228 culture supernatant Substances 0.000 description 10
- 229920001817 Agar Polymers 0.000 description 9
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 9
- 239000008272 agar Substances 0.000 description 9
- 230000000302 ischemic effect Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 208000028867 ischemia Diseases 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 241000186012 Bifidobacterium breve Species 0.000 description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 229930003268 Vitamin C Natural products 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 235000019154 vitamin C Nutrition 0.000 description 7
- 239000011718 vitamin C Substances 0.000 description 7
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 6
- 108020005091 Replication Origin Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 6
- 229940004120 bifidobacterium infantis Drugs 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 201000002818 limb ischemia Diseases 0.000 description 4
- 231100000053 low toxicity Toxicity 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 241001213452 Bifidobacterium longum NCC2705 Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006392 deoxygenation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 108091006047 fluorescent proteins Proteins 0.000 description 2
- 102000034287 fluorescent proteins Human genes 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- WONYMNWUJVKVII-UHFFFAOYSA-N 3,5-diiodothyropropionic acid Chemical compound IC1=CC(CCC(=O)O)=CC(I)=C1OC1=CC=C(O)C=C1 WONYMNWUJVKVII-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010060965 Arterial stenosis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241001655328 Bifidobacteriales Species 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000186013 Bifidobacterium asteroides Species 0.000 description 1
- 241000741973 Bifidobacterium breve DSM 20213 = JCM 1192 Species 0.000 description 1
- 241000186022 Bifidobacterium coryneforme Species 0.000 description 1
- 241000186020 Bifidobacterium dentium Species 0.000 description 1
- 241000186156 Bifidobacterium indicum Species 0.000 description 1
- 241000186147 Bifidobacterium longum subsp. suis Species 0.000 description 1
- 241000186153 Bifidobacterium magnum Species 0.000 description 1
- 241000186150 Bifidobacterium minimum Species 0.000 description 1
- 241000186148 Bifidobacterium pseudolongum Species 0.000 description 1
- 241000186160 Bifidobacterium pseudolongum subsp. globosum Species 0.000 description 1
- 241001468229 Bifidobacterium thermophilum Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009895 Colitis ischaemic Diseases 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 101000972324 Cynodon dactylon Leaf protein Proteins 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 1
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 108050008922 Histone-like DNA-binding proteins Proteins 0.000 description 1
- 101001060280 Homo sapiens Fibroblast growth factor 3 Proteins 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 208000009433 Moyamoya Disease Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 102000004459 Nitroreductase Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108091036333 Rapid DNA Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241001311541 Scardovia inopinata Species 0.000 description 1
- 206010063900 Steal syndrome Diseases 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000023569 ischemic bowel disease Diseases 0.000 description 1
- 201000008222 ischemic colitis Diseases 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000003975 mesenteric artery Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 108020001162 nitroreductase Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- LJPYJRMMPVFEKR-UHFFFAOYSA-N prop-2-ynylurea Chemical compound NC(=O)NCC#C LJPYJRMMPVFEKR-UHFFFAOYSA-N 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/30—Animals modified by surgical methods
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/101—Plasmid DNA for bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/50—Fibroblast growth factors [FGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
Definitions
- the present invention provides a novel secretion signal, a plasmid for transformation containing the secretion signal, a gene transport carrier comprising an anaerobic bacterium transformed with the plasmid, a pharmaceutical composition comprising the gene transport carrier, and these
- the present invention relates to a method for diagnosis or treatment of ischemic disease.
- Bifidobacteria which is a non-pathogenic intestinal bacterium that exists in the human intestine and forms flora and is known to be an extremely safe obligate anaerobic bacterium, has attracted attention.
- bifidobacteria transformed to express cytosine deaminase, an enzyme that converts 5-fluorocytosine, a prodrug of fluorouracil, to 5-FU, and TNF ⁇ , an antitumor protein Bifidobacteria have been developed (see Patent Documents 4 to 6).
- this transformed bifidobacteria When this transformed bifidobacteria is administered intravenously to a solid tumor animal model of anaerobic disease, it is engrafted and propagated specifically in an anaerobic disease tissue under hypoxia, and in a normal tissue that is not in an anaerobic environment. It has the feature of disappearing quickly (see Non-Patent Documents 1 and 2).
- angiogenesis therapy has been attempted to restore blood flow by developing neovascularization and collateral circulation.
- angiogenesis therapy has three types of angiogenesis therapy, cell transplantation, protein administration, and gene therapy.
- gene therapy has attracted attention from the viewpoint of minimally invasiveness.
- genes encoding hepatocyte growth factor (HGF) or vascular endothelial growth factor (VEGF) are injected into the vicinity of the affected area by intramuscular injection or intraarterial injection. The blood flow is restored by promoting angiogenesis in the vicinity of the affected area (see, for example, Non-Patent Documents 3 and 4).
- angiogenic therapies have attracted attention as one of the options for patients who cannot revascularize due to arteriolar level impairment or who are unable to perform surgery due to invasive problems.
- many clinical trials have been conducted in recent years, particularly with respect to angiogenesis therapy by gene therapy.
- angiogenesis therapy using conventional gene therapy has no lesion site specificity, so that systemic administration is impossible, and steal phenomenon that promotes angiogenesis in non-ischemic sites rather than ischemic sites.
- the efficiency of gene transfer and the control of the expression period of the transgene are difficult, and if there are complications that can worsen the symptoms due to angiogenesis, there is a great risk of application, etc. Applications still need to solve many problems.
- the present inventors have focused on anaerobic bacteria that engraft and proliferate specifically in anaerobic disease tissues, and by using transformed bifidobacteria, they specifically accumulate only in the ischemic site, and the ischemic site Succeeded in producing a gene transport carrier that produces a desired protein and disappears from the lesion site upon healing and no longer produces a protein (Patent Document 7).
- An object of the present invention is to provide a plasmid for transformation for transforming anaerobic bacteria, which enables highly efficient and stable secretion expression of the target protein, and gene transport comprising anaerobic bacteria transformed with the plasmid
- the object is to provide a carrier, a pharmaceutical composition containing the gene transport carrier, and a method for diagnosing or treating ischemic disease using the carrier.
- Patent Document 7 the present inventors prepared a transformation plasmid pFGF12a into which a gene encoding human FGF2 was incorporated, and transformed obligate anaerobes such as Bifidobacterium Longum 105A / pFGF12a, Bifidobacterium breve JCM1192 / pFGF12a, etc. are specifically accumulated and grown only at the ischemic disease site by systemic administration, and human FGF2 protein can be expressed and secreted at the ischemic disease site (Patent Document 7).
- obligate anaerobes such as Bifidobacterium Longum 105A / pFGF12a, Bifidobacterium breve JCM1192 / pFGF12a, etc.
- the present inventors have conducted intensive research to solve the problem, and as a result, found novel secretory signal peptides SP56 and SP67 derived from Bifidobacterium longum, and incorporated genes encoding these signal peptides.
- the anaerobic bacteria transformed with this plasmid have a much higher protein secretion than existing strains, and secrete the expressed protein stably even after long-term culture.
- the present invention was completed as a result of further research.
- a plasmid for transformation of anaerobic bacteria comprising a promoter unit, a secretory signal unit comprising DNA encoding a secretory signal peptide represented by SEQ ID NO: 1 or SEQ ID NO: 2, and diagnosis or treatment of ischemic disease
- the plasmid for transformation comprising a target gene unit containing DNA encoding a protein useful in the above.
- Proteins useful for diagnosis or treatment of ischemic diseases include fibroblast growth factor (FGF), endothelial growth factor (ECGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), Involved in vascular dilation such as prostaglandins such as angiogenesis-promoting proteins such as vascular growth factor (AGF), platelet-derived growth factor (PDGF), transforming growth factor ⁇ (TGF ⁇ ), angiopoietin and ephrin Factors, colony stimulating factors such as granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin Neurotrophin such as 3, insulin-like growth factor (IGF), platelet-derived vascular endothelial cell increase
- FGF fibroblast growth factor
- ECGF endothelial growth factor
- VEGF vascular endothelial growth factor
- the secretion signal unit further comprises DNA encoding a spacer peptide following the 3 ′ end of DNA encoding the secretion signal peptide represented by SEQ ID NO: 1 or SEQ ID NO: 2, ) Plasmid for transformation.
- the promoter contained in the promoter unit is the base sequence represented by SEQ ID NO: 13 or a sequence in which one or more bases of the base sequence are deleted, substituted or added (1) to (7) Plasmid for transformation.
- a gene transport carrier comprising an anaerobic bacterium transformed with the transformation plasmid of (1) to (9).
- a pharmaceutical composition comprising the gene transport carrier according to (10) to (12).
- the engraftment / proliferation promoter is at least one selected from the group consisting of maltose, lactulose, arabinose, xylose, galactose, glucose, lactose, melibiose, melezitose, and raffinose.
- a method for diagnosing or treating an ischemic disease comprising administering the gene transport carrier according to (10) to (12).
- the method according to (16), wherein the administration is systemic administration.
- the plasmid for transformation of the present invention is a novel plasmid useful for the production of transformed anaerobic bacteria for diagnosing and / or treating ischemic diseases having a novel secretion signal, and the plasmid for transformation of the present invention
- the anaerobic bacteria transformed with can secrete a large amount of the target protein stably.
- the gene transport carrier of the present invention consists of an anaerobic bacterium transformed with the plasmid for transformation of the present invention. Therefore, even when it is systemically administered, the gene transport carrier specifically grows in an ischemic disease site in an anaerobic environment. It is possible to sufficiently produce and secrete a protein having a therapeutic activity for ischemic disease at the disease site. Therefore, it is extremely useful as a gene transport carrier and as a therapeutic agent for ischemic diseases. In addition, since it is engrafted specifically in the ischemic disease site, even if it is systemic administration such as intravenous injection, it is accumulated specifically in the ischemic disease site and exhibits an effect.
- ischemia continues, it grows for a long time because the anaerobic environment of the ischemic disease site is maintained, but once the ischemia is ameliorated, it is no longer an anaerobic environment, so it cannot grow and quickly Disappear.
- the gene transport carrier of the present invention itself can express a protein useful for treatment, it is necessary to consider the efficiency of gene transfer into cells at or near the ischemic site as in the past. And can always exhibit high protein expression efficiency. Furthermore, since it is a carrier that is specifically delivered to an ischemic site, there is less risk of complications. Therefore, it is possible to perform angiogenesis treatment with higher safety and less invasiveness with fewer side effects and higher safety. Furthermore, by simultaneously expressing a marker on the gene transport carrier of the present invention, it can also be used for ischemic site diagnosis and treatment monitoring. Furthermore, the gene transport carrier of the present invention is capable of delivering a plurality of genes at the same time, and it is considered that more efficient and non-invasive treatment can be achieved by incorporating and administering a plurality of effective growth factors. .
- FIG. 1 shows a schematic diagram for the construction of a human FGF2 secretion shuttle plasmid. From the pCDshuttle plasmid, CD is replaced with hFGF2 (with His tag) to create pFGF-Hu, and SP26L20 is further inserted between the promoter and hFGF2 gene to create pHuSP26L20-FGF2, from which the His tag is removed. pHuSP26L20-FGF2-dHis was prepared.
- FIG. 2 shows a schematic diagram for the production of human FGF2 (tagged) secretion shuttle plasmid.
- FIG. 3 shows a schematic diagram for the production of human FGF2 (untagged) secretion shuttle plasmid.
- SP56L20 or SP67L20 was inserted into the linearized pHuSP26L20-FGF2-dHis fragment to prepare pHuSP56L20-FGF2-dHis or pHuSP67L20-FGF2-dHis, respectively.
- FIG. 4 shows a schematic diagram for the production of human FGF2 (untagged) secreted non-shuttle plasmid.
- FIG. 5 shows the results of Western blotting of the culture supernatants of FGF110 strain and FGF111 strain.
- M Molecular weight marker
- FGF110 FGF110 strain culture supernatant concentrate
- FGF111 FGF111 strain culture supernatant concentrate
- 12a FGF12a strain culture supernatant concentrate
- R Recombinant human FGF2.
- FGF110 strain, the FGF111 strain, and the FGF12a strain bands were confirmed at the same positions as the positive target recombinant (molecular weight: about 17 kDa).
- FIG. 6 shows NIH / 3T3 cell proliferation promoting activity of human FGF2 protein secreted from SP56 and SP67 strains.
- the vertical axis represents absorbance at 450-630 nm, and the horizontal axis represents human FGF2 concentration (ng / mL).
- Human FGF2 secreted from the SP56 and SP67 strains had a concentration-dependent cell growth promoting activity, similar to rhFGF2.
- FIG. 7 shows changes in human FGF2 secretion during long-term culture. Vertical axis: FGF2 secretion amount (ng / mL), horizontal axis: culture time.
- the FGF2 secretion amount was FGF110 strain, FGF111 strain, and FGF12a strain in descending order at any time point of 2day, 4day, and 7day.
- the amount of FGF2 secretion of the FGF12a strain was significantly reduced after the 4th day of culture, but stable expression / secretion was observed until the end in the FGF110 strain and the FGF111 strain.
- FIG. 8 shows the blood flow improvement effect of FGF110. Vertical axis: diseased / healthy side blood flow ratio, horizontal axis: days after the second operation.
- the FGF110 administration group showed a significant improvement in blood flow after day 14 compared to the PBS and BEshuttle groups. This effect lasted until day 36.
- the present invention relates to a novel secretion signal peptide derived from the genus Bifidobacterium, a secretion signal encoding the peptide, a plasmid for transformation containing the secretion signal, and the like.
- the present invention will be described in detail below.
- the plasmid for transformation of the present invention can secrete more expressed protein more stably by the action of a novel secretion signal unit. Therefore, any desired protein can be obtained by using such a transformation plasmid. It is characterized in that an excellent and highly practical transformed anaerobic bacterium that can be expressed and secreted with high efficiency can be produced.
- the present invention provides a transformation plasmid for transforming anaerobic bacteria, wherein the transformation plasmid comprises a promoter unit, a secretory signal peptide represented by SEQ ID NO: 1 or SEQ ID NO: 2.
- the present invention relates to the above plasmid for transformation comprising a secretory signal unit containing a coding DNA and a target gene unit containing a DNA encoding a protein (target protein) useful for diagnosis or treatment of ischemic disease.
- anaerobic bacteria means bacteria having anaerobic properties
- anaerobic properties means properties that can grow under conditions of little or no oxygen.
- anaerobic bacteria can be classified into facultative anaerobes that can grow even in the presence of oxygen and obligate anaerobic bacteria that cannot grow in the presence of oxygen.
- Obligate anaerobes such as Bifidobacterium are preferred.
- the anaerobic property possessed by the anaerobic bacterium of the present invention may be a property inherent in bacteria or may be obtained by mutation such as mutation or transformation. Therefore, in one embodiment of the present invention, the anaerobic bacterium is mutated to become an obligate anaerobic bacterium.
- a facultative anaerobic bacterium such as Lactobacillus may be used as long as it is mutated to obligate anaerobic.
- the transformation plasmid of the present invention is for transforming Bifidobacterium, and in a more preferred embodiment, for transforming Bifidobacterium longum.
- an “expression cassette” means a set of genes for expressing a specific protein or peptide fragment contained in a plasmid, and the set includes a promoter unit and a target gene unit, and optionally Other useful units may be included. Examples of other useful units include a gene encoding a signal peptide such as a secretion signal, a gene encoding a molecular chaperone of a protein encoded by a target gene, and the like.
- target gene unit refers to a set of genes relating to an expressed protein, including a gene encoding a target protein (expressed protein).
- the target gene unit may contain other DNA in addition to the gene encoding the target protein. Examples of other DNA that can be contained in the target gene unit include, but are not limited to, DNA encoding a peptide that labels an expressed protein such as His-Tag.
- the plasmid of the present invention contains a secretion signal unit so that the protein encoded by the plasmid for transformation of the present invention is produced in anaerobic cells and released outside the cells to exert a therapeutic effect.
- the “secretory signal unit” refers to a set of genes that encode an amino acid sequence for secreting an expressed protein outside the cell, including a secretory signal sequence.
- secretory signal or “secretory signal sequence” means a gene encoding a secretory signal peptide or a DNA sequence thereof.
- the secretory signal unit may include other DNA such as a DNA encoding a spacer peptide inserted between the target gene and the secretory signal sequence.
- the secretory signal sequence contained in the secretory signal unit of the present invention is a sequence encoding a novel secretory signal peptide represented by SP56 (SEQ ID NO: 1) or SP67 (SEQ ID NO: 2).
- the secretory signal sequence corresponding to the secretory signal peptide sequence represented by SEQ ID NO: 1 and SEQ ID NO: 2 includes the degenerate sequences thereof in addition to those represented by SEQ ID NO: 3 and SEQ ID NO: 4, respectively.
- amino acid sequence is referred to as “coding DNA” or “corresponding base sequence” to the amino acid sequence, etc. It is intended to contain an array.
- a novel secretory signal peptide represented by SP56 (SEQ ID NO: 1) or SP67 (SEQ ID NO: 2) is obtained from a total amino acid sequence registered in the genome database of Bifidobacterium longum using a secretory signal peptide prediction program. It is a secretory signal peptide further selected from the extracted candidates, and was confirmed by the present inventors for the first time as a useful secretory signal peptide.
- DNAs encoding SP56 and SP67 are anaerobic diseases. It is particularly suitable for use as a plasmid for transformation of anaerobic bacteria for diagnosis or treatment of ischemic diseases. Therefore, any transformation plasmid containing DNA encoding SP56 and SP67 is also encompassed by the present invention.
- the target gene unit of the present invention contains DNA encoding a protein useful for diagnosis or treatment of ischemic disease as an expressed protein.
- ischemia means a state of oxygen / nutrient deficiency in a tissue due to a decrease in arterial blood volume supplied to the tissue due to stenosis or occlusion of the blood vessel. Causes atrophy, degeneration, necrosis, etc.
- ischemic disease refers to a state in which tissue ischemia continues due to arterial stenosis or occlusion, regardless of the presence or absence of subjective symptoms, or an unfavorable state caused by such ischemia.
- ischemic diseases include, but are not limited to, ischemic heart diseases such as angina pectoris and myocardial infarction, cerebral ischemic diseases such as cerebral infarction, chronic cerebral ischemic diseases such as moyamoya disease, spinal cord
- ischemic heart diseases such as angina pectoris and myocardial infarction
- cerebral ischemic diseases such as cerebral infarction
- chronic cerebral ischemic diseases such as moyamoya disease
- spinal cord Examples include blood diseases, ischemic colitis, ischemic bowel diseases such as mesenteric artery occlusion, lower limb ischemic diseases such as obstructive arteriosclerosis and Buerger's disease, and retinal ischemic diseases such as diabetic retinopathy.
- ischemic site means a site where arterial blood volume, nutrition and oxygen are reduced due to ischemia, and is interchangeably used with “ischemic disease site” or “ischemic disease tissue”. Used.
- proteins useful for diagnosis or treatment of ischemic diseases include, but are not limited to, proteins having angiogenesis-promoting activity, proteins involved in vasodilation, and the like.
- proteins having angiogenesis-promoting activity include, but are not limited to, fibroblast growth factor (FGF), endothelial growth factor (ECGF), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), vascular growth factor (AGF), platelet-derived growth factor (PDGF), transforming growth factor ⁇ (TGF ⁇ ), angiopoietin, ephrin and the like.
- FGF fibroblast growth factor
- ECGF endothelial growth factor
- VEGF vascular endothelial growth factor
- HGF hepatocyte growth factor
- AGF vascular growth factor
- PDGF platelet-derived growth factor
- TGF ⁇ transforming growth factor ⁇
- angiopoietin ephrin
- Prostaglandins are involved in va
- G-CSF granulocyte colony stimulating factor
- GM-CSF granulocyte-macrophage colony stimulating factor
- NGF nerve growth factor
- brain-derived Examples thereof include neurotrophic factor (BDNF), neurotrophin (eg, neurotrophin 3), insulin-like growth factor (IGF), platelet-derived vascular endothelial growth factor (PD-ECGF), and the like.
- a particularly useful protein for diagnosis or treatment of ischemic disease is fibroblast growth factor 2 (FGF2).
- FGF2 fibroblast growth factor 2
- the “promoter unit” is a unit including a promoter and optionally a region related to other transcription control, and examples of the region related to other transcription control include an operator and a terminator.
- the promoter included in the promoter unit of the present invention may be any promoter as long as it functions in anaerobic bacteria.
- the promoter contained in the promoter unit of the present invention may be, for example, a Hu promoter (SEQ ID NO: 13) or a P37 promoter (SEQ ID NO: 16), preferably a Hu promoter.
- the promoter included in the promoter unit of the present invention is represented by a functional sequence equivalent in which one or more bases in the base sequence are deleted, substituted, or added as long as the function as a promoter is not lost. Also good.
- the promoter unit includes a terminator.
- Any terminator may be included as long as it functions in bifidobacteria, but a terminator of a gene encoding a histone-like DNA binding protein that functions in bifidobacteria (Hu terminator) is preferred, and in particular, SEQ ID NO: 38 Most preferred is a DNA represented by this nucleotide sequence or a sequence in which one or more bases are deleted, substituted or added.
- the secretory signal unit further comprises DNA encoding a spacer peptide following the 3 'end of DNA encoding the secretory signal peptide.
- the “spacer peptide” is a peptide inserted between the secretory signal peptide and the N-terminus of the target protein. Therefore, the DNA encoding the spacer peptide is the DNA present downstream of the secretion signal and upstream of the gene encoding the target protein in the expression cassette.
- the spacer peptide increases the secretion efficiency of the target protein.
- the spacer peptide is 1 to 25 amino acids long, more preferably 1 to 20 amino acids long, and even more preferably 5 to 20 amino acids long.
- the sequence of the spacer peptide is not particularly limited.
- the peptide represented by SEQ ID NO: 5 or a partial peptide including the N-terminus thereof and in the case of SP67, the peptide represented by SEQ ID NO: 6 or the peptide thereof It is a partial peptide containing the N-terminus.
- SEQ ID NOs: 5 and 6, respectively, are peptides composed of sequences from the N-terminal to 25th amino acids of the protein secreted by SP56 and SP67 in Bifidobacterium longum.
- the spacer peptide of the present invention is, for example, in the case of SP56, a partial sequence of 1 amino acid length consisting only of the first amino acid of the peptide represented by SEQ ID NO: 5, from the first amino acid of SEQ ID NO: 5 It is represented by a partial sequence of 15 amino acids in length up to the 15th amino acid, a partial sequence of 20 amino acids in length from the first amino acid to the 20th amino acid of SEQ ID NO: 5, or the entire sequence of 25 amino acids in length of SEQ ID NO: 5.
- a partial sequence of amino acid length, a partial sequence of 20 amino acids in length from the first amino acid to the 20th amino acid of SEQ ID NO: 6, May the like peptide represented by the entire sequence of 25 amino acids in length of SEQ ID NO: 6.
- the base sequences corresponding to the amino acid sequences represented by SEQ ID NO: 5 and SEQ ID NO: 6 are preferably those represented by SEQ ID NO: 7 and SEQ ID NO: 8, respectively.
- the secretion signal unit consists of the amino acid sequence represented by SEQ ID NO: 9 consisting of SP56 and a spacer peptide of 20 amino acids, or the sequence consisting of SP67 and a spacer peptide of 20 amino acids.
- the base sequences corresponding to the amino acid sequences represented by SEQ ID NO: 9 and SEQ ID NO: 10 are preferably those represented by SEQ ID NO: 11 and SEQ ID NO: 12, respectively.
- a plasmid for transformation includes a promoter unit, a secretory signal unit including a DNA encoding the secretory signal peptide represented by SEQ ID NO: 1 or SEQ ID NO: 2, and diagnosis or treatment of ischemic disease
- Any plasmid may be used as long as it contains a target gene unit containing a DNA encoding a useful protein, functions to transform anaerobic bacteria, and does not impair the anaerobic properties of the bacteria.
- a gene transport carrier comprising transformed anaerobic bacteria is used as a medicine, the plasmid for transformation is transferred horizontally to another bacterium in the body, such as Escherichia coli.
- the transformation plasmid is a non-shuttle plasmid.
- shuttle plasmid means a plasmid that can replicate in two or more different hosts, and is used interchangeably with “shuttle vector plasmid”.
- non-shuttle plasmid means a plasmid that can replicate in only one host. That is, in the above embodiment, the transformation plasmid has only a replication origin that functions in anaerobic bacteria to be transformed, and does not have a replication origin that functions in other bacteria, such as Escherichia coli, It is a plasmid that is not replicated by bacteria other than transformed anaerobes.
- the transformation plasmid of the present invention may further contain other useful genes.
- Other useful genes include, for example, a selectable marker gene such as spectinomycin resistance gene (SPCM), a replication origin such as bifidobacterial plasmid replication origin (pTB6), and a gene encoding a labeled protein such as GFP. Can be mentioned.
- the transformation plasmid of the present invention is pFGF110 (SEQ ID NO: 14) or pFGF111 (SEQ ID NO: 15).
- the plasmid for transformation of the present invention can be prepared, for example, as follows.
- at least one promoter unit, secretion signal unit, desired plasmid is added to a shuttle plasmid having a replication origin that functions in each of transformed bacteria and non-transformed bacteria, for example, bifidobacteria and E. coli.
- a shuttle plasmid can be prepared by inserting a DNA (target gene unit) encoding a protein useful for diagnosis or treatment of ischemic disease.
- a non-shuttle plasmid can be prepared by removing the replication origin of bacteria other than transformed bacteria from this shuttle plasmid.
- operation in each said process can be performed according to the well-known method of the field of genetic engineering.
- the present invention relates to a gene transport carrier comprising an anaerobic bacterium transformed with the above-described plasmid for transformation of the present invention.
- the gene transport carrier of the present invention is a gene transport carrier comprising the above-mentioned anaerobic bacteria transformed with the plasmid for transformation of the present invention, can grow in tissues under an anaerobic environment, and is intended.
- a protein having activity can be expressed and secreted.
- the gene transport carrier of the present invention is engrafted specifically in the ischemic disease site, the target protein is necessarily expressed and secreted specifically in the ischemic disease site. Therefore, the gene transport carrier of the present invention capable of expressing a protein used for diagnosis or treatment of ischemic disease can effectively diagnose or treat ischemic disease.
- the gene transport carrier of the present invention is engrafted specifically in the ischemic disease site, it is possible to diagnose the ischemic disease site by detecting the presence of the gene transport carrier.
- the detection of the gene transport carrier can be easily performed by labeling the gene transport carrier, for example. From the viewpoint of use in diagnosis of a disease, detection is preferably less invasive and preferably has less adverse effects on the living body due to the label. Therefore, in a preferred embodiment of the present invention, the gene transport carrier expresses a fluorescent protein as a protein useful for diagnosis. Examples of fluorescent proteins include various green fluorescent proteins (GFP) and red fluorescent proteins (RFP).
- the anaerobic bacteria used need not be toxic or have low toxicity.
- pathogenic bacteria such as Clostridium and Salmonella can be used in the present invention as long as they are rendered non-pathogenic. Therefore, in one embodiment of the present invention, the anaerobic bacterium of the present invention may be a mutated pathogenic bacterium with low toxicity.
- a bacterium that has been mutated to low toxicity may be reversely mutated to return to the original pathogenic bacterium, and may exhibit harmful effects. Therefore, it is preferably a naturally non-pathogenic bacterium. Therefore, in a preferred embodiment of the present invention, the anaerobic bacteria use non-pathogenic enteric bacteria.
- Bifidobacterium Bifidobacteria
- Bifidobacteria Bifidobacterium addressentis, Bifidobacterium angratum, Bifidobacterium animalis, Bifidobacterium asteroides, Bifidobacterium bifidum, Bifidobacterium Um Boum, Bifidobacterium breve, Bifidobacterium catenuratam, Bifidobacterium coelinum, Bifidobacterium coryneforme, Bifidobacterium kunichli, Bifidobacterium denticorens, Bifido Bacterium Dentium, Bifidobacterium galcumum, Bifidobacterium galinarum, Bifidobacterium globosum, Bifidobacterium in
- Bifidobacterium longum ATCC-15707 Bifidobacterium bifidum ATCC-11863, Bifidobacterium infantis ATCC-15697, etc. can be easily obtained from ATCC (The American American Type Culture Collection). Can do.
- the strain of each bacterium is not particularly limited.
- Bifidobacterium longum strain Bifidobacterium longum 105-A strain
- Bifidobacterium longum aE-194b strain examples include the Fidobacterium longum bs-601 strain and the Bifidobacterium longum M101-2 strain, with the Bifidobacterium longum 105-A strain being preferred.
- Bifidobacterium breve strains examples include Bifidobacterium breve standard strain (JCM1192), Bifidobacterium breve aS-1 strain, and Bifidobacterium breve I-53-8W strain. Among them, the Bifidobacterium breve standard strain and the Bifidobacterium breve aS-1 strain are preferable.
- Bifidobacterium infantis strains include Bifidobacterium infantis standard strain (JCM1222) and Bifidobacterium infantis I-10-5 strain. Bifidobacterium infantis standard strain and Bifidobacterium infantis I-10-5 strain are preferable.
- Bifidobacterium lactentis strains include Bifidobacterium lactentis standard strain (JCM1220).
- the gene transport carrier of the present invention can be produced by transforming any anaerobic bacterium to be transformed using the transformation plasmid of the present invention according to a known method in the field of genetic engineering.
- the present invention relates to a pharmaceutical composition comprising the gene transport carrier of the present invention.
- the pharmaceutical composition of the present invention is not particularly limited as long as it contains the gene transport carrier of the present invention.
- the gene transport carrier of the present invention may be contained in at least one kind, and may be contained in two or more kinds.
- the pharmaceutical composition of the present invention can be used in combination with a pharmaceutical composition or a therapeutic agent for ischemic disease containing a compound having an effect of treating ischemic disease other than the gene transport carrier of the present invention.
- the pharmaceutical composition of the present invention may contain any component in addition to the gene transport carrier of the present invention as long as the effects of the present invention are not hindered.
- optional components include pharmacologically acceptable carriers, excipients, diluents, gene transport carrier engraftment / proliferation promoters, and the like.
- engraftment / proliferation promoters include, but are not limited to: And sugars that can be assimilated by the transformed bacteria.
- the dosage form of the pharmaceutical composition of the present invention is not particularly limited, and examples thereof include a liquid or a solid preparation containing the gene transport carrier of the present invention.
- the solution is prepared by purifying the anaerobic bacteria culture medium of the gene carrier of the present invention, and adding an appropriate physiological saline solution or a replacement solution or a pharmaceutical additive to the ampule or a vial as necessary.
- an appropriate protective agent is added to the liquid and filled into ampoules or vials, and then lyophilized or L-dried, or an appropriate protective agent is added to the liquid and lyophilized or L-dried. This can be manufactured by filling ampules or vials.
- parenteral administration is preferred, and for example, intravenous injection, subcutaneous injection, local injection, intraventricular administration, etc. can be performed, Most preferred is intravenous injection, ie systemic administration.
- the dosage of the gene transport carrier of the pharmaceutical composition of the present invention is not particularly limited as long as it can grow at a disease site and is sufficient to express an effective therapeutic amount of an active protein. From the viewpoint of avoiding side effects as much as possible, it is preferable that the amount is as small as possible within a range in which a necessary therapeutic effect can be obtained.
- the dosage of the gene transport carrier in the pharmaceutical composition of the present invention can be appropriately selected according to the degree of disease, the patient's weight, age, and sex, and can be increased or decreased as appropriate according to the degree of improvement.
- the disease treatment activity exhibited by the anaerobic bacteria used, the type of protein having disease treatment activity produced by the anaerobic bacteria used, and the anaerobic bacteria used sets suitably according to the production amount of the said active protein, etc.
- the anaerobic bacterium of the present invention is divided into 10 6 to 10 12 cfu per 1 kg of body weight 1 to several times a day, one to several days continuously or at appropriate intervals. And administer. More specifically, a preparation containing 10 4 to 10 10 cfu / mL of the bifidobacteria cells of the present invention is diluted 1 to 1000 mL per adult directly or with an appropriate supplemental solution, 1 day per day. Divide into several times and administer continuously for 1 to several days.
- the bifidobacteria of the present invention may be administered at 10 6 to 10 12 cfu per kg of body weight 1 to several times a day, one or more days as necessary, continuously or at appropriate intervals. And administer.
- a preparation containing 10 4 to 10 10 cfu / mL of the bifidobacteria of the present invention is directly applied 1 to 1000 mL per adult several times a day, if necessary, for 1 to several days continuously. To administer.
- “combined with X and Y” includes any of X and Y in different forms, and X and Y in the same form (for example, a form containing X and Y). Including cases. In the case where X and Y are in different forms, the case where both X and Y further contain other components is also included.
- the gene transport carrier of the present invention engrafts and proliferates specifically to the ischemic disease site and does not proliferate in normal tissues that are not in an anaerobic environment. Therefore, a gene is delivered in a disease site-specific manner without local administration aiming at the ischemic disease site. Therefore, the pharmaceutical composition of the present invention is preferably administered systemically from the viewpoints of ease of administration and low invasiveness.
- the invention relates to a method for diagnosing or treating an ischemic disease comprising administering any of the gene transport carriers described above.
- the gene transport carrier of the present invention is administered to a subject having an ischemic disease.
- an administration method both oral administration and parenteral administration are possible, but parenteral administration is preferable.
- intravenous injection, subcutaneous injection, local injection, intraventricular administration, etc. can be performed. Most preferred.
- the gene transport carrier of the present invention is administered systemically. Since the gene transport carrier of the present invention can deliver a gene in an ischemic disease site-specific manner, it can be administered systemically by intravenous injection or the like without being directly administered to the affected area using a catheter or intramuscular injection. Even in this case, the effect can be exerted by engrafting and proliferating specifically in the ischemic disease site. Therefore, treatment that is very less invasive than conventional treatment methods is possible.
- Example 1 Identification of secretion signal peptide Secretion signal peptides SP56 and SP67 were identified by the following procedure. A signal that predicts the presence or absence of a secretion signal based on the entire amino acid sequence of the Bifidobacterium longum NCC2705 strain protein registered in the NCBI genome database (http://www.ncbi.nlm.nih.gov/genome/) Analysis was performed with the sequence prediction program SignalP 4.1 server (http://www.cbs.dtu.dk/services/SignalP/). Based on this analysis, TMHMM Server v.
- TM transmembrane region
- each secretory signal extends from the amino acid sequence N-terminal of each protein to the amino acid sequence estimated as the protease cleavage site by SignalP analysis.
- Peptide sequences SP56 and SP67
- the spacer peptide sequence was 20 amino acid residues that continued from the C-terminus of each signal sequence, and these were used as secretion signal units.
- the sequence of the secretion signal unit used is shown below. SP56 and its spacer peptide (SEQ ID NO: 9), SP67 and its spacer peptide (SEQ ID NO: 10).
- Example 2 Preparation of various hFGF2 secretion plasmids Table 1 shows PCR primers used for plasmid preparation.
- telomere sequence of hFGF2 is an artificial DNA sequence (SEQ ID NO: 31) in which the codon is optimized for Bifidobacteria based on the amino acid sequence of hFGF2 (a protein of about 18 kDa that started translation from AUG of GenBank Accession No. # NM_002006).
- PCR amplification was performed using 1 ng of this plasmid hFGF2 in pUC57 as a template and a primer set of FGF4 primer (forward) and FGF3 primer (reverse).
- the primer sequence was designed so that the insert fragment overlaps the end 15 bp of the vector fragment.
- PCR amplification was performed using PrimeSTAR HS (Premix) kit (Takara Bio Inc.) with each primer concentration of 0.2 ⁇ M and reaction volume of 50 ⁇ L.
- 30 cycles were carried out with 10 cycles at 98 ° C. (denaturation reaction), 5 seconds at 55 ° C. (annealing reaction) and 30 seconds at 72 ° C. (extension reaction), followed by 72 cycles.
- An additional extension reaction was carried out at 30 ° C. for 30 seconds to prepare an about 0.5 kbp hFGF2-HisTag insert fragment (insert fragment 1).
- Plasmid pCDshuttle International Publication No. 2009/128272 (SEQ ID NO: 32) PCR amplification was performed using 1 ng as a template and a primer set of FGF1 primer (forward) and FGF2 primer (reverse). Same as above. However, the PCR extension reaction was performed at 72 ° C. for 4 minutes. The length of vector fragment 1 is about 3.9 kbp.
- E. coli TOP10 competent cells (Invitrogen) were transformed according to the product instructions.
- the bacterial suspension after the transformation was applied to an LB agar medium containing 75 ⁇ g / mL spectinomycin and cultured at 37 ° C. overnight.
- the Escherichia coli colonies formed on the agar medium were cultured with shaking in an LB liquid medium containing 75 ⁇ g / mL spectinomycin at 37 ° C. overnight. From this, the plasmid was prepared using a QIAprep Spin Miniprep kit (manufactured by Qiagen). Extracted.
- PCR amplification was performed using PrimeSTAR HS (Premix) kit (Takara Bio Inc.) with each primer concentration of 0.2 ⁇ M and reaction volume of 20 ⁇ L. As the amplification program, 30 cycles were performed with 98 ° C for 10 seconds, 65 ° C for 5 seconds, and 72 ° C for 20 seconds, followed by extension reaction at 72 ° C for 30 seconds.
- a 2 kbp SP56L20 insert fragment amplification product (insert fragment 2) was prepared.
- the SP67L20 insert fragment (insert fragment 3) was prepared in the same manner as described above except that the SP67-ins_F1 primer (forward) and the SP67-ins_R1_FGF primer were used as PCR amplification primers.
- the PCR product was electrophoresed on a 0.8% agarose gel (containing ethidium bromide), and a gel containing a DNA band of about 4.3 kbp was cut out while being irradiated with UV.
- DNA was extracted from this gel using QIAquick Gel Extraction Kit (manufactured by Qiagen) to obtain vector fragment 2 (linearized pHu-FGF2 fragment, SEQ ID NO: 33).
- the plasmid was prepared using a QIAprep Spin Miniprep kit (manufactured by Qiagen). Extracted. Region containing the above human FGF2 secretion expression cassette (5′-Hu promoter-SP56L20-human FGF2 protein-His tag-Hu terminator-3 ′) or (5′-Hu promoter-SP67L20-human FGF2 protein-His tag) in the extracted plasmid The sequence of -Hu terminator-3 ') It carried out like (4). The extracted plasmids were named pHuSP56L20-FGF2 and pHuSP67L20-FGF2, respectively. The sequences of the regions containing the human FGF2 secretion expression cassette of each plasmid are shown in SEQ ID NOs: 34 and 35, respectively.
- PCR amplification was performed using the plasmid pHuSP26L20-FGF2 1 ng as a template and a primer set of FGF35 primer (forward) and FGF-His_R primer (reverse). It carried out like (1). However, the annealing temperature of PCR was 60 ° C., and the extension reaction was 35 ° C. at 72 ° C. The length of the insert fragment is about 0.5 kbp.
- reaction solutions were combined and subjected to proteinase K treatment, followed by deproteinization with phenol / chloroform, chloroform extraction, and alcohol precipitation by conventional methods.
- the alcohol-precipitated DNA was dissolved in 0.1 ⁇ TE to obtain non-shuttle plasmids pFGF110 (SEQ ID NO: 14) and pFGF111 (SEQ ID NO: 15).
- Example 3 Production of recombinant Bifidobacterium (1) Production of FGF110 strain and FGF111 strain Transformation of Bifidobacterium longum 105-A strain using the non-shuttle plasmids pFGF110 and pFGF111 prepared above. was performed by an electroporation system (Gen Pulser II, manufactured by Bio-Rad).
- Each bacterial suspension after incubation was applied to an IMR agar medium containing 75 ⁇ g / mL spectinomycin. These plates were placed in a sealed container together with the deoxygenation / carbon dioxide generating agent and cultured in an incubator set at 37 ° C. for 2 days.
- a transformant with plasmid pFGF110 is transformed with Bifidobacterium longum 105-A / pFGF110 strain (hereinafter referred to as FGF110 strain) and plasmid pFGF111.
- the body was Bifidobacterium longum 105-A / pFGF111 strain (hereinafter referred to as FGF111 strain).
- Bifidobacterium longum 105-A was transformed with shuttle plasmids pHuSP56L20-FGF2 and pHuSP67L20-FGF2 in the same manner as in (1) above.
- Bifidobacterium longum 105-A / pHuSP56L20-FGF2 strain hereinafter referred to as SP56 strain
- Bifidobacterium longum 105-A / pHuSP67L20-FGF2 strain hereinafter referred to as SP67 strain
- SP67 strain Bifidobacterium longum 105-A / pHuSP67L20-FGF2 strain
- Example 4 Analysis of expressed protein (1) Culture of recombinant Bifidobacterium genus Bifidobacterium longum 105A / pFGF12a strain described in the above FGF110 strain, FGF111 strain and Patent Document 7 (WO2013 / 008881) ( Hereinafter, the FGF12a strain) is inoculated into 10 mL of MRS (Becton Dickinson) liquid medium supplemented with spectinomycin (final concentration 75 ⁇ g / mL) and vitamin C added solution 100 ⁇ L, and anaerobic at 37 ° C. for 24 hours. It was cultured and used as an activated medium.
- MRS Becton Dickinson
- Anti FGF-2 human rabbit poly H-131, Santa Cruz Biotechnology Inc.
- TTBS TTBS
- Goat anti-rabbit IgG HRP Sura Cruz Biotechnology Inc.
- the membrane was allowed to emit light using Western Lightning Ultra (manufactured by PerkinElmer). This was analyzed with an imaging device (Fluor-S MAX, Bio-Rad).
- Example 5 Physiological activity measurement of FGF2 purified from His-tag from Bifidobacterium (1) Human FGF2 purification from culture supernatant of SP56 and SP67 strains Culture of SP56 and SP67 strains in the same manner as in Example 4 above Went. The culture broth was centrifuged to collect the supernatant, and ammonium sulfate precipitation was performed by a conventional method. Furthermore, affinity purification was performed using a protein purification kit having a histidine tag (TALON (registered commercial method) Metal Affinity Resin, manufactured by Takara Bio Inc.). The buffer was replaced with PBS using an ultrafiltration cassette (Amicon Ultra-4, 10K, Millipore) to obtain a purified human FGF2 solution. The amount of human FGF2 in this purified solution was measured using Quantikine ELISA FGF2 basic Immunoassay (R & D Systems; DFB50).
- TALON registered commercial method
- Metal Affinity Resin manufactured by Takara Bio Inc.
- FGF2 protein in the SP56 strain and SP67 strain secretion The physiological activity of FGF2 was that human FGF2 purified from the culture supernatant of SP56 strain and SP67 strain was purified from NIH / 3T3 cells (mouse fibers). Bud cell line) and evaluated by cell growth promoting activity. That is, NIH / 3T3 cells were cultured in DMEM medium (10% (v / v) FBS) under conditions of 37 ° C. and 5% CO 2 , and then 96 times in DMEM medium (5% (v / v) FBS). 1 ⁇ 10 3 cells were seeded on each well plate and cultured at 37 ° C. under 5% CO 2 conditions for 24 hours.
- purified human FGF2 derived from the above SP56 and SP67 strains or recombinant hFGF2 (R & D systems) is added to DMEM medium (5% (v / v) FBS) so that the FGF2 concentration becomes 0.25 ng / mL to 10 ng / mL.
- the medium mixed with was replaced.
- As a negative control a medium mixed with PBS ( ⁇ ) instead of the FGF2 solution was similarly replaced.
- the plate was cultured at 37 ° C. under 5% CO 2 for 4 days. After adding 100 ⁇ L of Cell Counting kit-8 (Dojindo Laboratories Co., Ltd.) to the above plate, further incubate for 2 hours at 37 ° C. under the condition of 5% CO 2 , at wavelengths of 450 nm and 630 nm (reference wavelength).
- the cell growth promoting activity against the NIH / 3T3 cells was measured by measuring the absorbance of the above.
- Example 6 Stability comparison of FGF2 secretion amount (1) Method Bifidobacterium longum 105A / pFGF12a strain described in WO2013 / 008881 and the glycerin stocks of the above FGF110 strain and FGF110 strain were treated with MRS (75 ⁇ g / mL spectino). Mycin, 1% vitamin C added solution) 1% inoculated into 10 mL of medium and anaerobically cultured at 37 ° C. for 24 hours to obtain an activated culture solution. Subsequently, 1% of the activated culture solution was inoculated into the same medium, and cultured in the same manner for 24 hours to obtain a subculture solution. Thereafter, the same passage was repeated every 24 hours.
- DMEM: MRS (9: 1) 75 ⁇ g / mL spectinomycin, containing 1% vitamin C added solution
- Human FGF2 secretion was measured on the 2nd, 4th, and 7th days after culturing from the glycerin stock.
- the culture solution in the medium for measuring human FGF2 was centrifuged to obtain a culture supernatant.
- the amount of FGF2 protein in the culture supernatant was measured using Quantikine ELISA FGF2 basic Immunoassay (R & D Systems; DFB50).
- FGF2 secretion amount was FGF110 strain, FGF111 strain, and FGF12a strain in descending order. In the FGF12a strain, the amount of FGF2 secretion significantly decreased after the fourth day of culture.
- Example 7 Transition of blood flow in limbs of chronic ischemic model mice administered with FGF110 strain
- a mouse model of lower limb ischemia was prepared, and human FGF2-secreting bifidobacteria were administered and examined.
- heparin sodium (dipro) diluted to 50 u / mL with physiological saline
- dipro diluted to 50 u / mL with physiological saline
- the femoral artery was ligated with 9-0 polypropylene thread, and the femoral artery center was excised.
- the wound was washed with physiological saline, the wound was sutured with 6-0 nylon thread.
- the temperature was recovered, and 0.2 mL of heparin was injected subcutaneously. Heparin 0.4 mL was also injected subcutaneously on the first and second days after the operation.
- Example 8 Plasmid retention stability after subculture in non-selective medium (1) Method In addition to the FGF110 strain and the FGF111 strain prepared above, 1% inoculation of a glycerol stock of the BEshuttle strain, which is a negative control strain, in 5 mL of MRS (75 ⁇ g / mL spectinomycin, 1% vitamin C added solution) medium And anaerobic culture at 37 ° C. for 24 hours to obtain an activated culture solution. 1% of this activated culture solution was inoculated into the same medium and cultured in the same manner for 24 hours to obtain a preculture solution.
- MRS 75 ⁇ g / mL spectinomycin, 1% vitamin C added solution
- MRS containing 1% vitamin C added solution
- MRS containing 1% vitamin C added solution
- the culture solution that had been passaged 7 times was appropriately diluted with an anaerobic diluent, applied to a BL agar medium, and anaerobically cultured at 37 ° C. for 2 days. 100 colonies formed on the BL agar medium were randomly selected, and these colonies were punctured into BL-bS and BL agar medium, and anaerobically cultured at 37 ° C. for 1 day.
- the transformation plasmid of the present invention makes it possible to provide a transformation plasmid for transforming anaerobic bacteria that enables high and stable secretion expression of the target protein. Therefore, compared with the conventional method, angiogenesis therapy can be easily performed with high efficiency and less invasiveness. In addition, since anaerobic bacteria transformed with such plasmids themselves become gene transport carriers, the efficiency of gene introduction into the target site is not a problem, and extremely high-efficiency treatment is performed compared to conventional methods. Is possible. This makes it possible to effectively treat subjects such as elderly people who could not be treated due to high invasiveness or systemic side effects, although angiogenesis therapy should be effective.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
Abstract
Description
しかしながら、さらに研究を続けていくうちに、上記特許文献7において主に用いられている形質転換プラスミドpFGF12aで形質転換したビフィドバクテリウム属細菌は発現タンパク質の分泌量が十分でなく、また分泌量も経時的に低下していくという安定性に欠けるものであるという新たな課題に直面した。
(1)嫌気性菌の形質転換用プラスミドであって、プロモーターユニット、配列番号1または配列番号2で表される分泌シグナルペプチドをコードするDNAを含む分泌シグナルユニット、および虚血性疾患の診断または治療に有用なタンパク質をコードするDNAを含む目的遺伝子ユニットを含む、前記形質転換用プラスミド。
(2)虚血性疾患の診断または治療に有用なタンパク質が、線維芽細胞増殖因子(FGF)、内皮細胞増殖因子(ECGF)、血管内皮増殖因子(VEGF)、肝実質細胞増殖因子(HGF)、血管増殖因子(AGF)、血小板由来増殖因子(PDGF)、トランスフォーミング増殖因子β(TGFβ)、アンギオポイエチン、エフリンなどの血管新生促進活性を有するタンパク質、プロスタグランジン類などの血管拡張に関与する因子、顆粒球コロニー刺激因子(G-CSF)、顆粒球-マクロファージコロニー刺激因子(GM-CSF)などのコロニー刺激因子、神経成長因子(NGF)、脳由来神経栄養因子(BDNF)、ニューロトロフィン3などのニューロトロフィン、インスリン様成長因子(IGF)、血小板由来血管内皮細胞増殖因子(PD-ECGF)からなる群から選ばれる一種である、(1)の形質転換用プラスミド。
(3)虚血性疾患の診断または治療に有用なタンパク質が、線維芽細胞増殖因子2(FGF2)である、(1)または(2)の形質転換用プラスミド。
(4)分泌シグナルユニットが、配列番号1または配列番号2で表される分泌シグナルペプチドをコードするDNAの3’末端に続けて、スペーサーペプチドをコードするDNAをさらに含む、(1)~(3)の形質転換用プラスミド。
(5)スペーサーペプチドが、1~25アミノ酸長であって、配列番号5または配列番号6で表されるアミノ酸配列のN末端のアミノ酸から始まる配列で表される、(4)の形質転換用プラスミド。
(6)分泌シグナルユニットが、配列番号9または配列番号10で表されるアミノ酸配列をコードするDNAである、(1)~(5)の形質転換用プラスミド。
(7)形質転換用プラスミドが、非シャトルプラスミドである、(1)~(6)の形質転換用プラスミド。
(8)プロモーターユニットに含まれるプロモーターが、配列番号13で表される塩基配列またはその塩基配列の1もしくは複数の塩基が欠失、置換もしくは付加された配列である、(1)~(7)の形質転換用プラスミド。
(9)形質転換用プラスミドが、pFGF110(配列番号14)またはpFGF111(配列番号15)の塩基配列で表される、(1)~(8)の形質転換用プラスミド。
(10)(1)~(9)の形質転換用プラスミドで形質転換された嫌気性菌からなる遺伝子輸送担体。
(11)嫌気性菌が、ビフィドバクテリウム属細菌である、(10)の遺伝子輸送担体。
(12)ビフィドバクテリウム属細菌が、ビフィドバクテリウム・ロンガムである、(11)の遺伝子輸送担体。
(13)(10)~(12)の遺伝子輸送担体を含む、医薬組成物。
(14)医薬組成物が、虚血性疾患部位における、遺伝子輸送担体の生着・増殖促進剤をさらに含む、(13)の医薬組成物。
(15)生着・増殖促進剤が、マルトース、ラクツロース、アラビノース、キシロース、ガラクトース、グルコース、ラクトース、メリビオース、メレジトース、ラフィノースからなる群より選択される少なくとも一種である、(14)の医薬組成物。
(16)(10)~(12)の遺伝子輸送担体を投与することを含む、虚血性疾患を診断または治療するための方法。
(17)投与が、全身投与である、(16)の方法。
以下本発明について詳細に説明する。
本発明の形質転換用プラスミドは、新規の分泌シグナルユニットの働きにより、より多くの発現タンパク質をより安定的に分泌することが可能となり、したがってかかる形質転換プラスミドを用いることにより、任意の目的タンパク質を発現し、高効率で分泌することができるという、優れた、実用性の高い形質転換された嫌気性菌を作製できるという点に特徴を有するものである。
本発明のプラスミドは、本発明の形質転換用プラスミドによりコードされるタンパク質が嫌気性菌体中で産生され、菌体外に放出されて治療効果を奏するように、分泌シグナルユニットを含む。
本明細書において、「虚血」とは、血管の狭窄や閉塞により、組織に供給される動脈血量が減少することによる組織の酸素・栄養欠乏状態を意味し、持続的な虚血は組織の萎縮や変性、壊死などを生じる。
本発明のプロモーターユニットに含まれるプロモーターは、嫌気性菌で機能するものであればいかなるものでもよく、例えば、ビフィズス菌由来の分泌シグナルの上流に位置しているプロモーターまたはビフィズス菌で機能するヒストン様DNA結合タンパク質をコードする遺伝子のプロモーター(Hu promoter)などを含む。一態様において、本発明のプロモーターユニットに含まれるプロモーターは、例えばHuプロモーター(配列番号13)や、P37プロモーター(配列番号16)であってもよく、好ましくはHuプロモーターである。本発明のプロモーターユニットに含まれるプロモーターは、プロモーターとしての機能を失わない範囲で、その塩基配列の1もしくは複数の塩基が欠失、置換もしくは付加されたもの(機能的同等物)で表されてもよい。
なお、配列番号5および配列番号6で表されるアミノ酸配列に対応する塩基配列は、好ましくは、夫々配列番号7および配列番号8で表されるものである。
例えば、通常の手法に従って、形質転換菌と形質転換菌以外の菌、例えばビフィズス菌と大腸菌でそれぞれ機能する複製開始点を有するシャトルプラスミドに、少なくとも1種の、プロモーターユニット、分泌シグナルユニット、所望の虚血性疾患の診断または治療に有用なタンパク質をコードするDNA(目的遺伝子ユニット)を挿入する事により、シャトルプラスミドを作製することができる。
なお、上記各工程における操作は、遺伝子工学分野の公知の方法に準じて行うことができる。
一側面において、本発明は、上記本発明の形質転換用プラスミドで形質転換された嫌気性菌からなる遺伝子輸送担体に関する。
また、ビフィドバクテリウム・ラクテンティスの株については、例えば、ビフィドバクテリウム・ラクテンティス標準株(JCM1220)を挙げることができる。
一側面において、本発明は、上記本発明の遺伝子輸送担体を含む、医薬組成物に関する。
本発明の医薬組成物は、本発明の遺伝子輸送担体を含有している限り特に制限はされない。本発明の遺伝子輸送担体は、少なくとも1種含まれていればよく、2種以上含まれていてもよい。さらに、本発明の医薬組成物は、本発明の遺伝子輸送担体以外の虚血性疾患治療効果を示す化合物を含有する医薬組成物や虚血性疾患治療剤と組み合わせて用いることができる。
本発明の医薬組成物の遺伝子輸送担体の投与量は、疾患部位において生育でき、且つ、有効治療量の活性タンパク質を発現するのに十分な量である限り特に制限はされないが、経済上の観点および副作用を可能な限り回避する観点から、必要な治療効果が得られる範囲においてできる限り少ない方が好ましい。
例えば、本発明の医薬組成物を用いる際には、用いる嫌気性菌の菌自体が示す疾患治療活性、用いる嫌気性菌が産生する疾患治療活性を有するタンパク質等の種類、および用いる嫌気性菌の当該活性タンパク質の産生量などによって、適宜設定する。
なお、本発明における「XとYと組み合わせてなる」には、XとYを別の形態としたもの、XとYを同一の形態(例えばXとYを含有する形態)としたもののいずれの場合も含む。また、XとYを別の形態としたものの場合、X、Yのいずれも他の成分をさらに含有している場合も含まれる。
一側面において、本発明は、前述されたいずれかの遺伝子輸送担体を投与することを含む、虚血性疾患を診断または治療するための方法に関する。
本発明の遺伝子輸送担体を用いることにより、高効率で安全性の高い診断または治療が可能となる。
本発明の方法において、本発明の遺伝子輸送担体を、虚血性疾患を有する対象に投与する。投与方法としては、経口投与、非経口投与共に可能であるが、非経口投与が好ましく、例えば静脈注射、皮下注射、局所注入、脳室内投与等を行うことができ、静脈注射、すなわち全身投与が最も好ましい。
以下の手順で、分泌シグナルペプチドSP56およびSP67を同定した。
NCBIのゲノムデータベース(http://www.ncbi.nlm.nih.gov/genome/)に登録されているビフィドバクテリウム・ロンガムNCC2705株由来タンパクの全アミノ酸配列を分泌シグナルの有無を予測するシグナル配列予測プログラムSignalP 4.1 server (http://www.cbs.dtu.dk/services/SignalP/)で解析した。この解析により、タンパクのN末端に分泌シグナルペプチド配列を有すると予測されたタンパクの一部のアミノ酸配列に対し、膜貫通領域(TM)を推定するプログラムTMHMM Server v. 2.0 (http://www.cbs.dtu.dk/services/TMHMM-2.0/)にてトポロジー解析を行った。このトポロジー解析結果より、タンパク質のN末端にTMが存在すると推定されたタンパク質を選定した。これらのタンパク質を、TMを有すると予想されるビフィドバクテリウム・ロンガムNCC2705株由来の分泌シグナルペプチドとして選定した。選定した分泌シグナルペプチドのアミノ酸配列に対応するビフィドバクテリウム・ロンガム105A株のアミノ酸配列において、各タンパク質のアミノ酸配列N末端からSignalP解析によってプロテアーゼ切断推定部位と推定されたアミノ酸配列までを各分泌シグナルペプチド配列(SP56およびSP67)とした。また、スペーサーペプチド配列は、各シグナル配列のC末端より続く20アミノ酸残基とし、これらを分泌シグナルユニットとした。用いた分泌シグナルユニットの配列を以下に示した。SP56とそのスペーサーペプチド(配列番号9)、SP67とそのスペーサーペプチド(配列番号10)。
(1)ヒトFGF2-HisTagインサート断片(インサート断片1)の調製
C末端にヒスチジンタグを融合したヒトFGF2をコードするDNAを含むプラスミド「hFGF2 in pUC57」をGenScript社より入手した。hFGF2のDNA配列は、hFGF2(GenBank Accession No. #NM_002006のAUGより翻訳開始の約18kDaのタンパク質)のアミノ酸配列に基づき、コドンをビフィズス菌用に最適化した人工DNA配列(配列番号31)である。このプラスミドhFGF2 in pUC57 1ngを鋳型として、FGF4プライマー(フォワード)およびFGF3プライマー(リバース)のプライマーセットを用いてPCR増幅を行った。プライマー配列は、インサート断片とベクター断片の末端15bpが重複するように設計した。各プライマー濃度を0.2μM、反応容量を50μLとして、PrimeSTAR HS(Premix)キット(タカラバイオ株式会社)を用いてPCR増幅を行った。増幅のプログラムとしては、98℃にて10秒(変性反応)、55℃にて5秒(アニーリング反応)、72℃にて30秒(伸長反応)を1サイクルとして、30サイクル行った後、72℃にて30秒追加伸長反応を行い、約0.5kbpのhFGF2-HisTagインサート断片(インサート断片1)を調製した。
プラスミドpCDshuttle(国際公開番号第2009/128272号)(配列番号32) 1ngを鋳型として、FGF1プライマー(フォワード)およびFGF2プライマー(リバース)のプライマーセットを用いてPCR増幅を上記と同様に行った。ただし、PCRの伸長反応は、72℃にて4分とした。ベクター断片1の長さは、約3.9kbpである。
上記で調製したインサート断片1とベクター断片1をIn-Fusion(登録商標)HD Cloningキット(タカラバイオ株式会社製)を用いて連結した。すなわち、マイクロチューブに、上記ベクター断片50ngとインサート断片13ngとを添加し、キット内の5×In-Fusion HD Enzyme premix 2μL、Cloning Enhancer 1μLをさらに添加し、0.1×TEバッファー(1mM Tris-HCl、0.1mM EDTA、pH7.5)にて反応液容量を10μLに調整した。これを37℃にて15分間保温した後、さらに50℃にて15分間保温した。その他の手順は、キットの製品説明書に従い、インフュージョン反応液1を調製した。
上記インフュージョン反応液1を用いて、大腸菌TOP10コンピテント細胞(インビトロジェン)の形質転換を製品説明書に従い行った。形質転換後の菌懸濁液は、75μg/mLスペクチノマイシン含有LB寒天培地に塗布し、37℃にて一晩培養した。上記寒天培地上に形成された大腸菌コロニーを75μg/mLスペクチノマイシン含有LB液体培地にて37℃にて一晩振とう培養し、これよりQIAprep Spin Miniprepキット(キアゲン社製)を用いてプラスミドを抽出した。抽出したプラスミドにおける上記ヒトFGF2発現カセット含む領域(5’-Huプロモーター-ヒトFGF2タンパク質-Hisタグ-Huターミネーター-3’)の配列を決定するため、Big Dye(登録商標)Terminator v3.1 Cycle Sequencingキット(アプライドバイオシステムズ社製)を用いてシーケンス反応を行った。抽出したプラスミドをpFGF-Huと名付けた。
(1)SP56L20およびSP67L20インサート断片(インサート断片2および3)の調製
ビフィドバクテリウム・ロンガム105-A株のゲノムDNAを鋳型として、表1に記載のSP56-ins_F1プライマー(フォワード)およびSP56-ins_R1_FGFプライマー(リバース)のプライマーセットを用いてPCR増幅を行った。プライマー配列は、インサート断片とベクター断片の末端15bpが重複するように設計した。各プライマー濃度を0.2μM、反応容量を20μLとして、PrimeSTAR HS(Premix)キット(タカラバイオ株式会社)を用いてPCR増幅を行った。増幅のプログラムとしては、98℃にて10秒、65℃にて5秒、72℃にて20秒を1サイクルとして、30サイクル行った後、72℃にて30秒伸長反応を行い、約0.2kbpのSP56L20インサート断片増幅産物(インサート断片2)を調製した。
SP67L20インサート断片(インサート断片3)は、PCR増幅プライマーとしてSP67-ins_F1プライマー(フォワード)およびSP67-ins_R1_FGFプライマーを用いた以外は、上記と同様に調製した。
プラスミドpFGF-Huを鋳型として、表1記載のFGF35プライマー(フォワード)およびHuProm_Rプライマー(リバース)のプライマーセットを用いて、上記インサート断片の調製と同様の方法にてPCR増幅を行った。ただし、PCRの反応容量を50μLとした。増幅のプログラムとしては、98℃にて10秒、65℃にて5秒、72℃にて4分30秒を1サイクルとして、30サイクル行った後、72℃にて30秒伸長反応を行い、約4.3kbpのベクター断片増幅産物を調製した。このPCR産物を0.8%アガロースゲル(エチジウムブロマイド含有)にて電気泳動を行い、UVにて照射しながら約4.3kbpのDNAバンドを含むゲルを切出した。このゲルからQIAquick Gel Extraction Kit(キアゲン社製)を用いてDNAを抽出し、ベクター断片2(直鎖化pHu-FGF2断片、配列番号33)とした。
上記で調製したインサート断片2またはインサート断片3とベクター断片2をそれぞれIn-Fusion(登録商標)HD Cloningキット(タカラバイオ株式会社製)を用いて連結した。すなわち、マイクロチューブに、上記ベクター断片増幅産物68ngとインサート断片増幅産物6.15ng(インサート断片2の場合)或いは6.55ng(インサート断片3の場合)とを添加し、キット内の5×In-Fusion HD Enzyme premix 2μL、Cloning Enhancer 1μLをさらに添加し、0.1×TEバッファー(1mM Tris-HCl、0.1mM EDTA、pH7.5)にて反応液容量を10μLに調整した。これを37℃にて15分間保温した後、さらに50℃にて15分間保温した。その他の手順は、キットの製品説明書に従い、インフュージョン反応液2を調製した。
上記インフュージョン反応液2を用いて、大腸菌HST16CRコンピテント細胞(タカラバイオ株式会社製)の形質転換を製品説明書に従い行った。形質転換後の菌懸濁液は、75μg/mLスペクチノマイシン含有LB寒天培地に塗布し、37℃にて一晩培養した。上記寒天培地上に形成された大腸菌コロニーを75μg/mLスペクチノマイシン含有LB液体培地にて37℃にて一晩振とう培養し、これよりQIAprep Spin Miniprepキット(キアゲン社製)を用いてプラスミドを抽出した。抽出したプラスミドにおける上記ヒトFGF2分泌発現カセット含む領域(5’-Huプロモーター-SP56L20-ヒトFGF2タンパク質-Hisタグ-Huターミネーター-3’)あるいは(5’-Huプロモーター-SP67L20-ヒトFGF2タンパク質-Hisタグ-Huターミネーター-3’)の配列を上記1.(4)と同様に行った。抽出したプラスミドをそれぞれpHuSP56L20-FGF2およびpHuSP67L20-FGF2と名付けた。各プラスミドのヒトFGF2分泌発現カセットを含む領域の配列をそれぞれ配列番号34および35に示す。
(1)SP26L20インサート断片(インサート断片4)の調製
ビフィドバクテリウム・ロンガム105AのゲノムDNA 80ngを鋳型として、Hu_SP26_Fプライマー(フォワード)およびFGF_SP26L20_Rプライマー(リバース)のプライマーセットを用いてPCR増幅を上記2.(1)と同様に行った。ただし、PCRの伸長反応は、72℃にて14秒、PCR溶液量は20μLとした。インサート断片の長さは、約0.1kbpである。
上記で調製したインサート断片4とベクター断片2を用いて、上記2.(3)と同様に、In-Fusion反応を行い、インフュージョン反応液3を調製した。ただしIn-fusion反応に用いたベクター量を50ng、インサート量を4.2ngとした。
上記インフュージョン反応液3を用いて、上記1.(4)と同様の方法にて、大腸菌TOP10コンピテント細胞の形質転換、組換え大腸菌からのDNA抽出、ヒトFGF2発現カセット含む領域(5’-Huプロモーター-SP26L20-ヒトFGF2タンパク質-Hisタグ-Huターミネーター-3’)の配列決定を行った。抽出したプラスミドをpHuSP26L20-FGF2と名付けた。
プラスミドpHuSP26L20-FGF2 1ngを鋳型として、FGF35プライマー(フォワード)およびFGF-His_Rプライマー(リバース)のプライマーセットを用いてPCR増幅を上記2.(1)と同様に行った。ただし、PCRのアニーリング温度は60℃、伸長反応は、72℃にて35秒とした。インサート断片の長さは、約0.5kbpである。
(5)ベクター断片3の調製
プラスミドpHuSP26L20-FGF2 1ngを鋳型として、FGF-His_Fプライマー(フォワード)およびFGF_SP26L20_Rプライマー(リバース)のプライマーセットを用いてPCR増幅を上記2.(2)と同様に行った。ただし、PCRのアニーリング温度は60℃、伸長反応は、72℃にて4分10秒とした。ベクター断片の長さは、約4kbpである。
上記で調製したインサート断片5とベクター断片3を用いて、上記2.(3)と同様に、In-Fusion反応を行い、インフュージョン反応液4を調製した。ただしIn-fusion反応に用いたベクター量を20ng、インサート量を4ngとした。
(7)大腸菌の形質転換3およびプラスミドpHuSP26L20-FGF2-dHis配列確認
上記インフュージョン反応液4を用いて、上記2.(4)と同様の方法にて大腸菌の形質転換、組換え大腸菌からのDNA抽出を行った。抽出したDNAを用いて、ヒトFGF2発現カセット含む領域(5’-Huプロモーター-SP26L20-ヒトFGF2タンパク質-Huターミネーター-3’)の配列決定を行った。抽出したプラスミドをpHuSP26L20-FGF2-dHisと名付けた。
(1)ヒトFGF2タンパク質をコードするDNAを含むベクター断片4の調製
プラスミドpHuSP26L20-FGF2-dHisを鋳型としたほかは、上記2.(2)と同様の方法にてPCRを行い、ベクター断片4(直鎖化pHuSP26L20-FGF2-dHis断片、配列番号36)を調製した。
上記で調製したインサート断片2または3(SP56またはSP67)およびベクター断片4を、上記2.(3)と同様の方法で行い、インフュージョン反応液5を調製した。ただし、ベクター量は75ngとした。
上記2.(4)と同様の手順にて、上記インフュージョン反応液5を用いて上記大腸菌HST16CRコンピテント細胞の形質転換、組換え大腸菌からのプラスミド抽出を行った。抽出したプラスミドの全長配列の決定を同様の手順にて行った。抽出したプラスミドをpHuSP56L20-FGF2-dHisおよびpHuSP67L20-FGF2-dHisと名付けた。
(1)プラスミドpHuSP56L20-FGF2-dHisおよびpHuSP67L20-FGF2-dHisからのpUCori除去
上記プラスミドpHuSP56L20-FGF2-dHisまたはpHuSP67L20-FGF2-dHis 3μgを制限酵素BamHI(Thermo Scientific社)およびBgl II(Thermo Scientific社)にて消化し、約0.7 kbpのpUC oriを含むDNA断片とそれ以外の部分(約3.8kbp)の2つの断片に切断した。この反応液を0.8%アガロースゲル(エチジウムブロマイド含有)にて電気泳動し、UVにて照射しながら約3.8kbpのDNAバンドを含むゲルを切出した。このゲルからQIAquick Gel Extraction Kit(キアゲン社製)を用いてDNAを抽出し、これらをそれぞれ直鎖化非シャトルプラスミドpFGF110およびpFGF111とした。
上記直鎖化非シャトルプラスミドのセルフライゲーションを、Rapid DNA Ligation Kit(Thermo Scientific社)を用いて以下のように行った。即ち、上記直鎖化非シャトルプラスミド400ngに、上記キット添付の5×Rapid Ligation Buffer 80μL、T4 DNA Ligase 8μLを加え、0.1×TEにて400μLとした。これを80μLずつ5本のマイクロチューブに分注し、22℃にて5分間反応させ、セルフライゲーション反応を行った。この反応液を一つにまとめ、Proteinase K処理、次いでフェノール・クロロホルムによる除タンパク質、クロロホルム抽出およびアルコール沈殿を常法にて行った。アルコール沈殿させたDNAを0.1×TEに溶解し、非シャトルプラスミドpFGF110(配列番号14)およびpFGF111(配列番号15)とした。
(1)FGF110株およびFGF111株の作製
上記で作製した非シャトルプラスミドpFGF110およびpFGF111のDNA溶液を用いて、ビフィドバクテリウム・ロンガム105-A株の形質転換をエレクトロポレーションシステム(ジーンパルサーII、バイオ・ラッド社製)により行なった。電気ショック(2kV、25μF、200Ω)後は、キュベット(2mmギャップ)に800μLのIMR液体培地と50μLのビタミンC添加液(100mLあたりアスコルビン酸35g、L-システイン塩酸塩一水和物2gおよび炭酸ナトリウム11gを含む溶液)との混合液を即時に添加し、これを滅菌済みの2mLマイクロチューブに回収した。この2mLチューブの蓋をゆるめて、脱酸素・炭酸ガス発生剤(アネロパック(登録商標)・ケンキ、三菱ガス化学株式会社製)とともに密閉容器に入れ、37℃に設定したインキュベーターにて3時間保温した。
シャトルプラスミドpHuSP56L20-FGF2およびpHuSP67L20-FGF2を用いて、上記(1)と同様の方法で、ビフィドバクテリウム・ロンガム105-A株の形質転換を行い、それぞれビフィドバクテリウム・ロンガム105-A/pHuSP56L20-FGF2株(以下、SP56株という)、およびビフィドバクテリウム・ロンガム105-A/pHuSP67L20-FGF2株(以下、SP67株という)を得た。
ベクター骨格であるWO2011/093467に記載のpBEshuttle(配列番号37)を用いて、上記(FGF110株およびFGF111株の作製)と同様の方法で、ビフィドバクテリウム・ロンガム105-A株の形質転換を行い、ビフィドバクテリウム・ロンガム105-A/pBEshuttle株(以下、BEshuttle株という)を得た。
(1)組換えビフィドバクテリウム属細菌の培養
上記FGF110株、FGF111株および特許文献7(WO2013/008881)に記載のビフィドバクテリウム・ロンガム105A/pFGF12a株(以下、FGF12a株という)を、スペクチノマイシン(終濃度75μg/mL)およびビタミンC添加液100μLを添加したMRS(ベクトン・ディッキンソン社製)液体培地10mLに植菌し、37℃にて24時間嫌気培養し、活性化培養液とした。次に、DMEM(Cat No.11885-084:ライフテクノロジーズ社製):MRSを9:1の割合で混合した培地20mLに、ビタミンC添加液100μL、スペクチノマイシンを75μg/mLになるよう添加し、上記活性化培養液100μLを植菌した。これを37℃にて15時間嫌気培養した。
上記組換えビフィズス菌培養液の上清を常法に従いトリクロロ酢酸(TCA)沈殿し、1×SDSサンプルバッファーにて再溶解した。これを、95℃にて3分間加熱処理し、ウェスタン解析に供した。
(3)ウェスタンブロッティング
上記各培養上清濃縮物(培養上清0.2mL相当)および陽性対照であるリコンビナントヒトFGF2(Peprotech社,分子量17.2kDa)をミニプロティアン(登録商標)TGXTMゲル(4~20%)(バイオ・ラッド社製)にて電気泳動し、ゲルをPVDF膜(メンブラン)(iBlot Transfer Stacks、ライフテクノロジーズ社製)にiBlotトランスファーデバイス(ライフテクノロジーズ社製)を用いて転写した。ブロッティング終了後のPVDF膜をブロッキング(2% ECL Prime Blocking agent(GEヘルスケアジャパン株式会社製)in TTBS)した。一次抗体として、Anti FGF-2 human rabbit poly(H-131、Santa Cruz Biotechnology Inc.)を加え、4℃にて一晩振とうした。一次抗体反応後、メンブランをTTBSにて約5分の洗浄を6回繰り返し、二次抗体Goat anti-rabbit IgG HRP(Santa Cruz Biotechnology Inc.)を加え、室温にて1時間振とうした。抗体反応終了後のメンブランを、Western Lightning Ultra(パーキンエルマー社製)を用いて発光させた。これをイメージング装置(Fluor-S MAX、バイオ・ラッド)にて解析した。
結果を図5に示す。FGF110株およびFGF111株について、予想される分子量、約20kDaのバンドが確認された。
(1)SP56株およびSP67株の培養上清からのヒトFGF2精製
上記実施例4と同様の方法でSP56株およびSP67株の培養を行った。この培養液を遠心分離して上清を回収し、硫酸アンモニウム沈殿を常法にて行った。さらに、ヒスチジンタグを有するタンパク質用精製キット(TALON(登録商法) Metal Affinity Resin、タカラバイオ社製)を用いてアフィニティー精製した。これを、限外ろ過カセット(アミコンウルトラ-4、10K、ミリポア)を用いてバッファーをPBSに置換し、精製ヒトFGF2溶液を得た。この精製溶液中のヒトFGF2量を、Quantikine ELISA FGF2 basic Immunoassay(R&D Systems;DFB50)を用いて測定した。
FGF2の生理活性は、SP56株およびSP67株の培養上清より上記のように精製したヒトFGF2をNIH/3T3細胞(マウス線維芽用細胞株)に添加し、細胞増殖促進活性にて評価した。即ち、NIH/3T3細胞をDMEM培地(10%(v/v)FBS)にて37℃、5%CO2の条件下で培養後、DMEM培地(5%(v/v)FBS)にて96穴プレートに1×103個ずつ播種し、37℃にて5%CO2の条件下で24時間培養した。次に、上記SP56株およびSP67株由来ヒトFGF2精製物またはリコンビナントhFGF2(R&D systems)を、FGF2濃度が0.25ng/mL~10ng/mLになるようDMEM培地(5%(v/v)FBS)と混合した培地と交換した。陰性対照として、FGF2溶液の代わりにPBS(-)を混合した培地への交換も同様に行った。このプレートを37℃にて5%CO2の条件下で4日間培養した。
上記プレートに、Cell Counting kit-8(株式会社同仁化学研究所)100μLずつを添加後、さらに2時間37℃にて5%CO2の条件下で保温し、波長450nmと630nm(参照波長)での吸光度を測定することにより上記NIH/3T3細胞に対する細胞増殖促進活性を測定した。
結果を図6に示す。
SP56、SP67株より分泌したヒトFGF2は、濃度依存的な細胞増殖促進活性を有していた。
(1)方法
WO2013/008881に記載のビフィドバクテリウム・ロンガム105A/pFGF12a株および上記FGF110株、FGF110株のグリセリンストックを、MRS(75μg/mLスペクチノマイシン、1%ビタミンC添加液)培地10mLに1%植菌し、37℃にて24時間嫌気培養し、活性化培養液とした。ついで、活性化培養液を同培地に1%植菌し、同様に24時間培養して継代培養液とした。以降24時間毎に同様の継代を繰り返した。
ヒトFGF2分泌量測定前日には、上記継代培養液を、ヒトFGF2測定用培地であるDMEM:MRS(9:1)(75μg/mLスペクチノマイシン、1%ビタミンC添加液含有)培地へと0.5%植菌し、37℃で13時間培養した。ヒトFGF2分泌量測定はグリセリンストックからの培養後2日目、4日目、7日目に行った。
ヒトFGF2測定用培地での培養液を遠心分離して培養上清を得た。この培養上清中のFGF2タンパク量を、Quantikine ELISA FGF2 basic Immunoassay(R&D Systems;DFB50)を用いて測定した。
結果を図7に示す。
FGF2分泌量は、高い順から、FGF110株、FGF111株、FGF12a株であった。
FGF12a株は、培養4日目以降にFGF2分泌量が大幅に低下した。
本発明の遺伝子輸送担体の、虚血性疾患部位での治療効果を検証するため、下肢虚血のマウスモデルを作製し、ヒトFGF2分泌ビフィズス菌を投与して検討した。
(1)マウス下肢虚血モデル(necrotic model)の作製
実験動物は19週齢、メスのBALB/cマウス(日本エスエルシー)を使用した。麻酔はソムノペンチル(共立製薬株式会社)を2.5mg/mLに希釈したものを体重20gあたり0.4mL腹腔内に注射した。麻酔と同時にヘパリンナトリウム(二プロ)(生理食塩水にて50u/mLに希釈)を0.2mL腹腔内に注射した。腹部から下腿の除毛を行ったのち大腿動脈を9-0ポリプロピレン糸にて結紮し、大腿動脈中枢を切除した。創内を生理食塩水で洗浄後、創を6-0ナイロン糸にて縫合した。術後復温し、ヘパリン0.2mLを皮下注射した。術後1、2日目にもヘパリン0.4mLを皮下注射した。
初回術後6日目に初回同様麻酔を行い、ヘパリン投与後に大腿動脈末梢を結紮、切除した。初回同様術後2日目までヘパリン投与を行った。また組換えビフィズス菌投与後より連日10%マルトース1mLを腹腔内投与した。
マウスを麻酔後、レーザードップラー血流計(Moor Instruments社製)を用いて血流測定を行った。足根下腿関節以下から指先までの血流を両側について血流を定量し、患側/健側比にて表した。血流測定は2回目手術をday0として、day2、7、14、21、36に行った。
ヒトFGF2分泌ビフィズス菌であるFGF110株の凍結製剤にPBSを添加して菌濃度を調製して使用した。下肢虚血モデル2回目手術をday0として、day3、4、11、18、25、32に尾静脈より0.6×109cfuを一日二回投与した。対比群として、BEshuttle株の凍結製剤を同量投与した群、およびPBSを同水分量(0.2mL)投与した群を設定した。
(1)方法
上記で作製したFGF110株およびFGF111株に加え、陰性対照株であるBEshuttle株のグリセリンストックをMRS(75μg/mLスペクチノマイシン、1%ビタミンC添加液)培地5mLに1%植菌し、37℃にて24時間嫌気培養し、活性化培養液とした。この活性化培養液を同培地に1%植菌し、同様に24時間培養し、前培養液とした。以降、スペクチノマイシンを含まない非選択培地であるMRS(1%ビタミンC添加液含有)培地5mLへ植菌し、24時間毎に同培地に継代し、非選択培地での継代培養を繰り返した。7回継代した培養液を嫌気性希釈液にて適宜薄め、これをBL寒天培地に塗布し、37℃にて2日間嫌気培養した。
BL寒天培地上に形成したコロニーを無作為に100個選択し、これらコロニーをBL-bSおよびBL寒天培地に穿刺し、37℃にて1日間嫌気培養した。各培地上の穿刺痕におけるビフィズス菌の生育を確認し、(BL-bS寒天培地上での生育箇所)/(BL寒天培地上での生育箇所)×100を算出し、プラスミド保持菌率とした。
Claims (17)
- 嫌気性菌の形質転換用プラスミドであって、プロモーターユニット、配列番号1または配列番号2で表される分泌シグナルペプチドをコードするDNAを含む分泌シグナルユニット、および虚血性疾患の診断または治療に有用なタンパク質をコードするDNAを含む目的遺伝子ユニットを含む、前記形質転換用プラスミド。
- 虚血性疾患の診断または治療に有用なタンパク質が、線維芽細胞増殖因子(FGF)、内皮細胞増殖因子(ECGF)、血管内皮増殖因子(VEGF)、肝実質細胞増殖因子(HGF)、血管増殖因子(AGF)、血小板由来増殖因子(PDGF)、トランスフォーミング増殖因子β(TGFβ)、アンギオポイエチン、エフリンなどの血管新生促進活性を有するタンパク質、プロスタグランジン類などの血管拡張に関与する因子、顆粒球コロニー刺激因子(G-CSF)、顆粒球-マクロファージコロニー刺激因子(GM-CSF)などのコロニー刺激因子、神経成長因子(NGF)、脳由来神経栄養因子(BDNF)、ニューロトロフィン3などのニューロトロフィン、インスリン様成長因子(IGF)、血小板由来血管内皮細胞増殖因子(PD-ECGF)からなる群から選ばれる一種である、請求項1に記載の形質転換用プラスミド。
- 虚血性疾患の診断または治療に有用なタンパク質が、線維芽細胞増殖因子2(FGF2)である、請求項1または2に記載の形質転換用プラスミド。
- 分泌シグナルユニットが、配列番号1または配列番号2で表される分泌シグナルペプチドをコードするDNAの3’末端に続けて、スペーサーペプチドをコードするDNAをさらに含む、請求項1~3のいずれか一項に記載の形質転換用プラスミド。
- スペーサーペプチドが、1~25アミノ酸長であって、配列番号5または配列番号6で表されるアミノ酸配列のN末端のアミノ酸から始まる配列で表される、請求項4に記載の形質転換用プラスミド。
- 分泌シグナルユニットが、配列番号9または配列番号10で表されるアミノ酸配列をコードするDNAである、請求項1~5のいずれか一項に記載の形質転換用プラスミド。
- 形質転換用プラスミドが、非シャトルプラスミドである、請求項1~6のいずれか一項に記載の形質転換用プラスミド。
- プロモーターユニットに含まれるプロモーターが、配列番号13で表される塩基配列またはその塩基配列の1もしくは複数の塩基が欠失、置換もしくは付加された配列である、請求項1~7のいずれか一項に記載の形質転換用プラスミド。
- 形質転換用プラスミドが、pFGF110(配列番号14)またはpFGF111(配列番号15)の塩基配列で表される、請求項1~8のいずれか一項に記載の形質転換用プラスミド。
- 請求項1~9のいずれか一項に記載の形質転換用プラスミドで形質転換された嫌気性菌からなる遺伝子輸送担体。
- 嫌気性菌が、ビフィドバクテリウム属細菌である、請求項10に記載の遺伝子輸送担体。
- ビフィドバクテリウム属細菌が、ビフィドバクテリウム・ロンガムである、請求項11に記載の遺伝子輸送担体。
- 請求項10~12のいずれか一項に記載の遺伝子輸送担体を含む、医薬組成物。
- 医薬組成物が、虚血性疾患部位における、遺伝子輸送担体の生着・増殖促進剤をさらに含む、請求項13に記載の医薬組成物。
- 生着・増殖促進剤が、マルトース、ラクツロース、アラビノース、キシロース、ガラクトース、グルコース、ラクトース、メリビオース、メレジトース、ラフィノースからなる群より選択される少なくとも一種である、請求項14に記載の医薬組成物。
- 請求項10~12のいずれか一項に記載の遺伝子輸送担体を投与することを含む、虚血性疾患を診断または治療するための方法。
- 投与が、全身投与である、請求項16に記載の方法。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2974333A CA2974333C (en) | 2015-01-19 | 2016-01-18 | Therapeutic agent for ischemic disease |
SG11201705915VA SG11201705915VA (en) | 2015-01-19 | 2016-01-18 | Therapeutic agent for ischemic diseases |
EP16740115.7A EP3249043B1 (en) | 2015-01-19 | 2016-01-18 | A transformation plasmid |
CN201680006161.9A CN107208108B (zh) | 2015-01-19 | 2016-01-18 | 缺血性疾病治疗药 |
KR1020177023311A KR101892722B1 (ko) | 2015-01-19 | 2016-01-18 | 허혈성 질환 치료제 |
US15/544,565 US10993972B2 (en) | 2015-01-19 | 2016-01-18 | Therapeutic agent for ischemic diseases |
JP2016570626A JP6258526B2 (ja) | 2015-01-19 | 2016-01-18 | 虚血性疾患治療薬 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015007760 | 2015-01-19 | ||
JP2015-007760 | 2015-01-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016117508A1 true WO2016117508A1 (ja) | 2016-07-28 |
Family
ID=56417053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/051293 WO2016117508A1 (ja) | 2015-01-19 | 2016-01-18 | 虚血性疾患治療薬 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10993972B2 (ja) |
EP (1) | EP3249043B1 (ja) |
JP (1) | JP6258526B2 (ja) |
KR (1) | KR101892722B1 (ja) |
CN (1) | CN107208108B (ja) |
CA (1) | CA2974333C (ja) |
SG (1) | SG11201705915VA (ja) |
WO (1) | WO2016117508A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018062225A1 (ja) * | 2016-09-28 | 2018-04-05 | 株式会社アネロファーマ・サイエンス | ビフィドバクテリウム属細菌の遺伝子発現用プロモーター |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108611367B (zh) * | 2018-04-24 | 2019-11-19 | 北京诺思兰德生物技术股份有限公司 | 一类通过质粒载体介导的基因治疗重组载体 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011093465A1 (ja) * | 2010-01-29 | 2011-08-04 | 株式会社アネロファーマ・サイエンス | 形質転換用プラスミド |
WO2014010758A1 (ja) * | 2012-07-13 | 2014-01-16 | 学校法人帝京平成大学 | 抗腫瘍剤、腫瘍検出用マーカー及び経口ワクチン剤 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6416754B1 (en) | 1994-03-03 | 2002-07-09 | The Board Of Trustees Of The Leland Stanford Junior University | Anaerobe targeted enzyme-mediated prodrug therapy |
US6984513B2 (en) | 1994-03-03 | 2006-01-10 | The Board Of Trustees Of The Leland Stanford Junior University | Anaerobe targeted enzyme-mediated prodrug therapy |
JP3642755B2 (ja) | 2000-09-21 | 2005-04-27 | 純 天野 | 嫌気性菌を用いた遺伝子治療用医薬 |
CA2342040C (en) | 2000-09-21 | 2012-07-10 | Kyowa Hakko Kogyo Co., Ltd. | Anaerobic bacterium as a drug for cancer gene therapy |
JP3998171B2 (ja) * | 2001-06-15 | 2007-10-24 | 独立行政法人科学技術振興機構 | シグナルペプチドの判別方法、及びそのためのコンピュータプログラム |
CN101448940A (zh) | 2006-05-24 | 2009-06-03 | 阿内罗药物科学株式会社 | 基因转运载体的制备方法 |
DK2274422T3 (en) * | 2008-04-17 | 2017-07-03 | Anaeropharma Science Inc | expression |
US9730968B2 (en) * | 2008-04-17 | 2017-08-15 | Anaeropharma Science, Inc. | Therapeutic agent for ischemic diseases |
CA2841451A1 (en) * | 2011-07-13 | 2013-01-17 | Anaeropharma Science, Inc. | Ischemic disease therapeutic agent |
KR20170002403A (ko) | 2014-05-01 | 2017-01-06 | 가부시키가이샤 아네로파마·사이엔스 | 이종 폴리펩티드 발현 카세트 |
-
2016
- 2016-01-18 SG SG11201705915VA patent/SG11201705915VA/en unknown
- 2016-01-18 WO PCT/JP2016/051293 patent/WO2016117508A1/ja active Application Filing
- 2016-01-18 KR KR1020177023311A patent/KR101892722B1/ko active IP Right Grant
- 2016-01-18 EP EP16740115.7A patent/EP3249043B1/en active Active
- 2016-01-18 JP JP2016570626A patent/JP6258526B2/ja active Active
- 2016-01-18 US US15/544,565 patent/US10993972B2/en active Active
- 2016-01-18 CN CN201680006161.9A patent/CN107208108B/zh active Active
- 2016-01-18 CA CA2974333A patent/CA2974333C/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011093465A1 (ja) * | 2010-01-29 | 2011-08-04 | 株式会社アネロファーマ・サイエンス | 形質転換用プラスミド |
WO2011093468A1 (ja) * | 2010-01-29 | 2011-08-04 | 株式会社アネロファーマ・サイエンス | 形質転換用プラスミド |
WO2014010758A1 (ja) * | 2012-07-13 | 2014-01-16 | 学校法人帝京平成大学 | 抗腫瘍剤、腫瘍検出用マーカー及び経口ワクチン剤 |
Non-Patent Citations (4)
Title |
---|
DATABASE GenBank [O] 17 June 2013 (2013-06-17), XP055461422, Database accession no. EPE38071 * |
DATABASE GenBank [O] 7 November 2005 (2005-11-07), XP055461414, Database accession no. AAX44931 * |
FUJITA K. ET AL.: "Identification and molecular cloning of a novel glycoside hydrolase family of core 1 type O-glycan-specific endo-alpha-N- acetylgalactosaminidase from Bifidobacterium longum", J BIOL CHEM, vol. 280, no. 45, 2005, pages 37415 - 37422, XP002383896 * |
See also references of EP3249043A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018062225A1 (ja) * | 2016-09-28 | 2018-04-05 | 株式会社アネロファーマ・サイエンス | ビフィドバクテリウム属細菌の遺伝子発現用プロモーター |
Also Published As
Publication number | Publication date |
---|---|
JP6258526B2 (ja) | 2018-01-10 |
CA2974333A1 (en) | 2016-07-28 |
US10993972B2 (en) | 2021-05-04 |
CA2974333C (en) | 2018-09-25 |
EP3249043B1 (en) | 2019-11-06 |
EP3249043A1 (en) | 2017-11-29 |
CN107208108B (zh) | 2019-05-17 |
US20180360893A1 (en) | 2018-12-20 |
SG11201705915VA (en) | 2017-08-30 |
KR20170105102A (ko) | 2017-09-18 |
KR101892722B1 (ko) | 2018-08-28 |
JPWO2016117508A1 (ja) | 2017-12-07 |
CN107208108A (zh) | 2017-09-26 |
EP3249043A4 (en) | 2018-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5841432B2 (ja) | 形質転換用プラスミド | |
US8383398B2 (en) | Expression vector | |
JP6258526B2 (ja) | 虚血性疾患治療薬 | |
US9730968B2 (en) | Therapeutic agent for ischemic diseases | |
WO2013008881A1 (ja) | 虚血性疾患治療薬 | |
US20100266545A1 (en) | Obligately anaerobic mutant lactic acid bacterium and preparation method therefor, and expression vector functioning in obligately anaerobic lactic acid bacterium | |
US20130095072A1 (en) | Therapeutic agent for ischemic diseases | |
KR20150082827A (ko) | glmS 기반의 숙주 벡터 시스템 | |
WO2022007741A1 (en) | Genetically engineered live bacteria and methods of constructing the same | |
KR20240015030A (ko) | E5의 분비를 위한 재조합 발현 벡터 및 이로 형질전환된약독화 살모넬라 균주 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16740115 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2016570626 Country of ref document: JP Kind code of ref document: A Ref document number: 2974333 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11201705915V Country of ref document: SG |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2016740115 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20177023311 Country of ref document: KR Kind code of ref document: A |